Back to search results
NCT07652970

Tele-CE in Severe Stroke

Recruiting
NAAges 18–80InterventionalTreatment
University of Illinois at Chicago
~40 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Tele-CETele-Control

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Corticomotor excitability using transcranial magnetic stimulation (TMS)
Measured over Changes will be calculated from baseline (pre) to immediately after the intervention (post).
+3 more outcomes measured

Conditions

Stroke

Explore related trials

Stroke

Where it's being run

1 sites across 1 states
Illinois1

Who to contact

Shravni Deshmukh
[email protected]
312-996-9056
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Single, monohemispheric stroke
Chronic stroke (\> 6 months prior)
Severe stroke (Fugl-Meyer Lower Extremity motor scale score \< 21 or 6 Minute Walk Test distance \< 300m)

Exclusion

Use of anti-spasticity medications
Existence of other neurological disorders
Have brainstem or cerebellar lesions.
Mini-Mental State Examiniation score of \<21, to ensure participants have the cognitive capacity to consent and can understand instructions both in-person and during remote supervision.
Non-English-speaking individuals
Bone, joint or soft tissue injury
Uncontrolled medical conditions (such as uncontrolled hypertension, untreated cardiac disease, or untreated pulmonary disease)
Unable to see the tablet and zoom screen
Unable to move non-paretic ankle (\< 5 degrees of ankle ROM)
Fugl-Meyer Lower Extremity sensory scale score \< 6
Previous adverse reaction to TMS
Skull abnormalities or fractures
Concussion within the prior 6 months
Unexplained, recurring headaches
Implanted cardiac pacemaker
Metal implants in the head or face
History of seizures or epilepsy
Use of medications that could alter cortical excitability or increase risk of seizure (e.g., antidepressants, antipsychotics, anxiolytics, anticonvulsants)
Current pregnancy
Skin hypersensitivity at any sites of stimulation, including the scalp, thoracolumbar spine, and peripheral limbs
History of contact dermatitis at any of the sites of stimulation
History of allodynia and/or hyperalgesia
Active skin infection
Skin lesions
Deep vein thrombosis
Any other skin or scalp condition that could be aggravated by stimulation
Implanted electronic, metallic, or highly conductive devices near site of stimulation that cannot be removed without permission from a health professional

What this trial measures

  • Corticomotor excitability using transcranial magnetic stimulation (TMS)Changes will be calculated from baseline (pre) to immediately after the intervention (post).

    Single-pulse transcranial magnetic stimulation (TMS) will be used to assess the corticomotor excitability from the tibialis anterior muscle. Higher values indicate more corticomotor excitability.

  • Transcallosal Inhibition using transcranial magnetic stimulation (TMS)Changes will be calculated from baseline (pre) to immediately after the intervention (post).

    Inhibition from the stimulated hemisphere to the non-stimulated hemisphere will be quantified as a measure of the ipsilateral silent period (iSP) using single pulse transcranial magnetic stimulation (TMS) and motor evoked potentials (MEPs) will be recorded from the tibialis anterior muscle of the leg ipsilateral to TMS stimulation. Higher values indicate more inhibition from the stimulated hemisphere to the non-stimulated hemisphere.

  • Cutaneous reflex excitability using peripheral nerve stimulation (PNS)Changes will be calculated from baseline (pre) to immediately after the intervention (post).

    Peripheral nerve stimulation (PNS) will be used to assess the cutaneous reflexes excitability from the deep peroneal nerve.

  • Muscle StrengthChanges will be calculated from baseline (pre) to immediately after the intervention (post).

    Muscle strength of the affected and unaffected hip flexors, hip abductors, hip adductors, knee flexors, knee extensors, ankle dorsiflexors and ankle plantarflexors will be measured using handheld dynamometry.